insulin degludec vs Insulin glargine (Toujeo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin degludec · Tresiba
Marketed by Novo Nordisk
NCT00982644 · Phase 3 · completed
The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)
Result source: NCT00982644
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin degludec | Insulin glargine (Toujeo) |
|---|---|---|
| HbA1c, change | -1.1% vs -1.2%vs IGlarNCT0098264422 other results
| —Not reported |
| Body weight, change (kg) | 1.2 vs 3vs Insulin GlargineNCT0250116115 other results
| —Not reported |
| HbA1c below 7% | 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116 | —Not reported |
| Fasting plasma glucose, change | -3.9 vs -3.7vs Insulin GlargineNCT0250116115 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05802862 | —Not reported |
HbA1c, change
- insulin degludec
- -1.1% vs -1.2%vs IGlarNCT00982644
22 other results
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.4% vs -1.6% NCT04795531
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.5% vs -1.4% NCT02762578
- -0.1% vs -0.1% NCT03268005
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -1.3% vs -0.4% NCT01676116
- -0.6% vs -0.5% NCT04588259
- -0.1% vs -0.1% NCT01570751
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -0.8% NCT01959529
- -0.9% vs -1.1% NCT00982644
- -0.5% vs -0.5% NCT03078478
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- -0.5% vs 0% NCT04538352
- Insulin glargine (Toujeo)
- —Not reported
Body weight, change (kg)
- insulin degludec
- 1.2 vs 3vs Insulin GlargineNCT02501161
15 other results
- 2.9 vs 1.7 NCT03078478
- 2.9 vs -1 NCT02607306
- 4.1 vs -1 NCT02607306
- 2.3 vs 2.8 NCT04795531
- 0.2 vs -2.5 NCT03172494
- 0.5 vs 2.2 NCT02501161
- -1.4 vs 1.8 NCT01952145
- 1.2 vs 1.1 NCT03268005
- 1.3 vs -2.5 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 2.8 vs 2.2 NCT02762578
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- 2 vs -0.8 NCT01676116
- -8.6 vs 1.4 NCT04538352
- Insulin glargine (Toujeo)
- —Not reported
HbA1c below 7%
- insulin degludec
- 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116
- Insulin glargine (Toujeo)
- —Not reported
Fasting plasma glucose, change
- insulin degludec
- -3.9 vs -3.7vs Insulin GlargineNCT02501161
15 other results
- -2.0 vs -1.4 NCT03078478
- -4.1 vs -2.6 NCT02607306
- -4.0 vs -2.6 NCT02607306
- -3.0 vs -3.0 NCT04795531
- -3.6 vs -1.9 NCT03172494
- -4.0 vs -3.8 NCT02501161
- -3.0 vs -0.6 NCT01676116
- 0.6 vs 0.7 NCT03268005
- -3.5 vs -1.9 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -3.0 vs -1.6 NCT02762578
- -2.8 vs -2.3 NCT02911948
- 0.4 vs 0.2 NCT04588259
- -0.8 vs 0 NCT01570751
- -2 vs -4.4 NCT02648217
- Insulin glargine (Toujeo)
- —Not reported
3-point MACE (% with event)
- insulin degludec
- —Not posted · NCT05802862
- Insulin glargine (Toujeo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. insulin degludec: 5 of 5 rows · Insulin glargine (Toujeo): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin degludec | Insulin glargine (Toujeo) |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wka,b,c,d,e NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -1.29% (n=1651) @ 52wkb,c,d,e NCT02451137 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 21.5%once dailyf NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results2% NCT01959529 · Phase 3 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence 2.7% NCT04795531 · Phase 3 · registry result, not featured evidence 6.7%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 8.5%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | 14.8%g NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%once dailyf NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results0% NCT01959529 · Phase 3 —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination — NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence — NCT04795531 · Phase 3 · registry result, not featured evidence 0.6%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence — NCT03268005 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 2.2%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence 0.3%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | —g NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 15.1%once dailyf NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results38.6% NCT01959529 · Phase 3 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 3.7% NCT03336528 · Phase 4 · registry result, not featured evidence 6.7% NCT04588259 · Phase 3 · registry result, not featured evidence 5.1% NCT04795531 · Phase 3 · registry result, not featured evidence 4%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 20.8% NCT03078478 · Phase 3 · registry result, not featured evidence 7% NCT03268005 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.8%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence —Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination 3.1%Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT01570751 · Phase 3 · registry result, not featured evidence | 19.4%g NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | once dailyf nasopharyngitis 23.9% headache 13.8% diarrhoea 10.8% NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 23 more resultsonce weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination emergency room visit for bilateral knee pain 1.2% emergency room visit for congestive heart failure 1.2% emergency room visit for wound infection 1.2% NCT03336528 · Phase 4 · registry result, not featured evidence diabetic retinopathy 14.7% hyperlipidaemia 14% upper respiratory tract infection 9.3% NCT04588259 · Phase 3 · registry result, not featured evidence covid-19 4.8% influenza 3.1% diabetic retinopathy 2% NCT04795531 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.7% nasopharyngitis 5.1% diabetic retinopathy 3.4% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence nasopharyngitis 19% upper respiratory tract infection 18.1% diarrhoea 9% NCT03078478 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 33.6% weight increased 7% pharyngitis 5.5% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence lipase increased 10% headache 9.3% nasopharyngitis 8.9% NCT01676116 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 1.4% NCT01570751 · Phase 3 · registry result, not featured evidence | g trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 32 weeks versus 52 weeks.
- fPopulation comparability has not been reviewed for 25 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin degludec
show 22 more results
show 2 more results
show 15 more results
+ 110 further endpoints in the CSV export.
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · Insulin glargine (Toujeo)'s landscape